Linked Life Data

8326169

Source:http://linkedlifedata.com/resource/pubmed/id/8326169

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1993-8-10
pubmed:abstractText
The proportion of relapses among all patients detected each year increased steadily since the initiation of the national leprosy control program in China with dapsone monotherapy in 1955, reaching 18%-24% in the more leprosy-endemic provinces along the coast. Relapses were also reported in the formerly rifampin-plus-dapsone-treated patients. So far, only three paucibacillary relapses after 6 months of multidrug therapy (MDT) have been reported, and these were due to misclassification at the time of diagnosis. A short course of MDT should be given to all formerly dapsone- and/or rifampin-plus-dapsone-cured patients for the prevention of relapse. If not, they should be screened every 1 to 2 years for any possible signs of relapse, and MDT given when needed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0148-916X
pubmed:author
pubmed:issnType
Print
pubmed:volume
61
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1-7
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
Problems of leprosy relapse in China.
pubmed:affiliation
Leprosy Unit, Beijing Tropical Medicine Research Institute, China.
pubmed:publicationType
Journal Article